Catalyst Pharmaceuticals Delays Key FIRDAPSE Patent Validity Trial by Two Months
CPRX sits 18% above its 52-week low of $19.05.
Summary
Catalyst Pharmaceuticals announced a two-month delay in the bench trial concerning the validity of its FIRDAPSE patents, pushing the start date to May 18, 2026.
Key Events · Legal and Risk Events · CPRX
-
FIRDAPSE Patent Trial Delayed
The District Court for the District of New Jersey has postponed the bench trial regarding the validity of FIRDAPSE patents from March 23, 2026, to May 18, 2026.
-
Ongoing Patent Litigation
The trial involves a dispute with Hetero USA, Inc. over the validity of Orange Book-listed patents for FIRDAPSE, which expire between 2032 and 2037.
Analysis · CPRX · Life Sciences
This filing reports a procedural delay in a critical patent litigation case for Catalyst Pharmaceuticals' key product, FIRDAPSE. While a delay itself is not a resolution, it prolongs the period of uncertainty surrounding the patent validity, which is crucial for the company's long-term revenue stream from FIRDAPSE. The patents in question extend to 2037, making the outcome highly significant for future exclusivity. Investors should monitor the rescheduled trial date for further developments.
At the time of this filing, CPRX was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $19.05 to $26.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.